Last reviewed 2026-04-20 · How we verify

Gentamicin C2B (MICRONOMICIN)

Phase 2 active Small molecule

Gentamicin C2B (generic name: MICRONOMICIN) is a micronomicin drug. It is currently in Phase 2 development.

Gentamicin C2B works by binding to bacterial ribosomes and inhibiting protein synthesis.

Gentamicin C2B, also known as Micronomicin, is a small molecule antibiotic in the micronomicin class. Its target is unknown, and it is not FDA-approved for any indications. Gentamicin C2B has a half-life of 2.1 hours, but its bioavailability and commercial status are unknown. As a result, it is not widely available or used in clinical practice. Further research is needed to fully understand its properties and potential applications.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MICRONOMICIN
Drug class	micronomicin
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like factories that make proteins to keep you healthy. Gentamicin C2B is like a special tool that gets inside these factories and stops them from making proteins, which ultimately kills the bacteria that are making you sick.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gentamicin C2B CI brief — competitive landscape report
Gentamicin C2B updates RSS · CI watch RSS

Frequently asked questions about Gentamicin C2B

What is Gentamicin C2B?

Gentamicin C2B (MICRONOMICIN) is a micronomicin drug.

How does Gentamicin C2B work?

Gentamicin C2B works by binding to bacterial ribosomes and inhibiting protein synthesis.

What is the generic name of Gentamicin C2B?

MICRONOMICIN is the generic (nonproprietary) name of Gentamicin C2B.

What drug class is Gentamicin C2B in?

Gentamicin C2B belongs to the micronomicin class. See all micronomicin drugs at /class/micronomicin.

What development phase is Gentamicin C2B in?

Gentamicin C2B is in Phase 2.

Drug class: All micronomicin drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing